- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: Lymphoplasmacytic Lymphoma.
Displaying page 1 of 2.
EudraCT Number: 2008-001353-17 | Sponsor Protocol Number: SPC2996-107 | Start Date*: 2008-11-05 | ||||||||||||||||
Sponsor Name:Santaris Pharma A/S | ||||||||||||||||||
Full Title: A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN’S LYMPHOMA | ||||||||||||||||||
Medical condition: Follicular Lymphoma (FL); Lymphoplasmacytic (lymphoplasmacytoid) Lymphoma (LPL) / Waldenstrom’s macroglobulinemia (WM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) HU (Prematurely Ended) CZ (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005129-22 | Sponsor Protocol Number: FIL_BRB | Start Date*: 2014-06-09 | |||||||||||
Sponsor Name:Fondazione Italiana Linfomi | |||||||||||||
Full Title: FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN –BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA’S PATIENTS AT FIRST RELAPSE | |||||||||||||
Medical condition: NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA’S PATIENTS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002602-52 | Sponsor Protocol Number: BAY80-6946/16349 | Start Date*: 2012-10-19 | |||||||||||||||||||||
Sponsor Name:Bayer AG | |||||||||||||||||||||||
Full Title: Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas | |||||||||||||||||||||||
Medical condition: Patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas or patients with follicular lymphoma relapsed after or refractory to standard therapy. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) SE (Completed) PL (Completed) AT (Completed) PT (Completed) HU (Completed) DK (Prematurely Ended) IE (Completed) GR (Completed) LU (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016725-34 | Sponsor Protocol Number: C18083/2048 | Start Date*: 2010-05-21 | |||||||||||
Sponsor Name:Cephalon, Inc. | |||||||||||||
Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL) | |||||||||||||
Medical condition: Non-Hodgkin’s Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023407-95 | Sponsor Protocol Number: MO25455 | Start Date*: 2011-10-17 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin’s lympho... | |||||||||||||
Medical condition: Patients with relapsed or refractory CD20+ follicular non-Hodgkin’s lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma, marg... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) SK (Completed) LT (Completed) HU (Completed) FR (Completed) ES (Completed) SI (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001591-80 | Sponsor Protocol Number: INFL08 | Start Date*: 2008-05-12 | ||||||||||||||||||||||||||
Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI | ||||||||||||||||||||||||||||
Full Title: PHASE II STUDY OF LENALIDOMIDE IN COMBINATION WITH RITUXIMAB (R) FOR THE TREATMENT OF INDOLENT NON FOLLICULAR NON HODGKIN LYMPHOMA | ||||||||||||||||||||||||||||
Medical condition: Histological proved diagnosis of B-cell CD20-positive non follicular NHL according to REAL/WHO Classification: a. small lymphocytic lymphoma b. lymphoplasmacytic lymphoma/Waldenstrom macroglobul... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001563-21 | Sponsor Protocol Number: IM-T-hLL2-18 | Start Date*: 2005-02-02 |
Sponsor Name:Immunomedics, Inc. | ||
Full Title: A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia | ||
Medical condition: Waldenström's Macroglobulinemia (WM) is an uncommon B-cell lymphoproliferative disorder that predominantly involves older patients with a slight male preponderance. WM resembles myeloma and chroni... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001088-38 | Sponsor Protocol Number: BAY80-6946/17833 | Start Date*: 2015-12-09 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in p... | |||||||||||||
Medical condition: Patients with relapsed indolent non-Hodgkin's lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Completed) DK (Prematurely Ended) ES (Prematurely Ended) GB (Completed) FR (Ongoing) PL (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) HU (Completed) SK (Ongoing) GR (Restarted) BG (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002247-86 | Sponsor Protocol Number: 602030 | Start Date*: 2005-12-05 |
Sponsor Name:Royal Devon and Exeter NHS Foundation Trust | ||
Full Title: Peripheral Blood Stem Cell Mobilisation with Cyclophosphamide and Methylprednisolone in Patients with Myeloma and Indolent Lymphoma– a prospective single arm study with historical controls | ||
Medical condition: Plasma cell myeloma Non hodgkins lymphomas - follicular lymphoma, Mantle cell lymphoma, Lymphoplasmacytic lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003579-22 | Sponsor Protocol Number: MO39107 | Start Date*: 2017-08-02 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Roche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann- La Roche | ||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE II STUDY EXPLORING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB ADMINISTERED IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB ANTI-CD20 THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMP... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Relapsed/Refractory Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Completed) DE (Completed) LV (Completed) GR (Completed) SK (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004177-17 | Sponsor Protocol Number: OMB110918 | Start Date*: 2010-06-22 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Ri... | |||||||||||||
Medical condition: Indolent B-cell Non-Hodgkin’s Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) FR (Completed) DE (Prematurely Ended) PL (Prematurely Ended) IT (Completed) GR (Completed) GB (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005297-10 | Sponsor Protocol Number: DCL-16-001 | Start Date*: 2021-05-19 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Cellectar Biosciences, Inc. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobu... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Part A: MM (multiple myeloma), CLL/SLL(chronic lymphocytic leukemia/small lymphocytic lymphoma), LPL/WM(lymphoplasmacytic lymphoma/ Waldenstrom's Macroglobulinemia), MZL(marginal zone lymphoma), MC... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: CZ (Completed) GR (Ongoing) FR (Ongoing) ES (Ongoing) FI (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005225-81 | Sponsor Protocol Number: VALYM | Start Date*: 2021-04-28 | ||||||||||||||||
Sponsor Name:LYSARC | ||||||||||||||||||
Full Title: A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA | ||||||||||||||||||
Medical condition: RELAPSE/REFRACTORY B-CELL LYMPHOMA | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) BE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019248-37 | Sponsor Protocol Number: IILINFL09 | Start Date*: 2010-12-30 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular Non-Hodgkin’s Lymphoma | |||||||||||||
Medical condition: Patients with advanced untreated Indolent non Follicular non-Hodgkin Lymphomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000302-37 | Sponsor Protocol Number: RHMCAN1278 | Start Date*: 2017-09-06 | ||||||||||||||||||||||||||
Sponsor Name:University Hospital Southampton Foundation Trust | ||||||||||||||||||||||||||||
Full Title: A phase IIa study of Rituximab and Varlilumab in relapsed or refractory B-cell malignancies | ||||||||||||||||||||||||||||
Medical condition: Relapsed or refractory B-Cell malignancies | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005338-13 | Sponsor Protocol Number: ONC-2011-004 | Start Date*: 2013-08-17 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Istituto Clinico Humanitas - Humanitas Cancer Center | ||||||||||||||||||||||||||||||||||||||
Full Title: OFATUMUMAB-BENDAMUSTINE FOR RELAPSED/REFRACTORY INDOLENT LYMPHOMA: A MULTICENTER PHASE 2 TRIAL | ||||||||||||||||||||||||||||||||||||||
Medical condition: Non-Hodgkin's Follicular and Non-Follicular indolent lymphomas, relapsed/refractory | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004657-11 | Sponsor Protocol Number: VI-Plt-01 | Start Date*: 2012-03-30 | |||||||||||
Sponsor Name:FONDAZIONE PROGETTO EMATOLOGIA | |||||||||||||
Full Title: Open label multicenter study of Eltrombopag for the treatment of Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs) | |||||||||||||
Medical condition: Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002692-16 | Sponsor Protocol Number: APL-B-012-02 | Start Date*: 2004-10-27 |
Sponsor Name:PharmaMar SA unipersonal | ||
Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory Indolent Non-Hodgkin’s Lymphoid Neoplasms. | ||
Medical condition: Non-Hodgkin’s Lymphomas (NHLs) relapsing or refractory | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006370-15 | Sponsor Protocol Number: WM RV 0426 (2008_15/0837) | Start Date*: 2009-01-23 | ||||||||||||||||
Sponsor Name:CHRU de Lille | ||||||||||||||||||
Full Title: A multicenter phase I/II dose excalation study of lenalidomide in relapse/refractory Waldenström macroglobulinemia | ||||||||||||||||||
Medical condition: Maladie de Waldenstöm rédicivante ou réfractaire | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004830-81 | Sponsor Protocol Number: FIL_BArT | Start Date*: 2015-12-24 | ||||||||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | ||||||||||||||||||
Full Title: A multicenter study to evaluate the anti-viral activity of an interferon-free treatment with ledipasvir/sofosbuvir (G1 and G4) and sofosbuvir/velpatasvir (G2 and G3) for patients with hepatitis C v... | ||||||||||||||||||
Medical condition: Patients with hepatitis C virus-associated indolent B-cell lymphomas | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.